Patent applications from Bellevue, Wash.-based Aiberry Inc. describe further aspects of its artificial intelligence (AI)-powered mental health screening platform that is designed to improve efficiency and save time for healthcare providers.
Psychiatric indications, such as depression, schizophrenia and bipolar disorder, share a common feature of elevated expression of pro-inflammatory markers in the periphery and/or central nervous system. Based on this, it is believed that combined immuno- and neuromodulatory activities of phosphodiesterase 4 (PDE4) inhibitors may represent a promising new therapeutic strategy for various psychiatric indications.
Researchers from Anhui University presented the discovery and preclinical evaluation of novel negative allosteric modulators (NAMs) of the metabotropic glutamate mGlu5 receptor.
Enveric Biosciences Inc. has identified three novel compounds from its EVM301 series with the potential to offer a first-in-class approach to address difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations.
Neuronetics Inc. gained expanded approval in Japan for its transcranial magnetic stimulation (TMS) system to treat major depressive disorder called the Neurostar TMS, helping the Malvern, Pa.-based company increase its footprint in Asia.
Mira Pharmaceuticals Inc. has entered into a licensing agreement with Miralogx LLC for exclusive rights in the U.S., Canada and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analogue for depressive disorder treatments.
Küleon LLC (formerly Psilosterics LLC) has announced a trifunctional serotonergic small molecule that is a full 5-HT2C receptor agonist and full antagonist of the 5-HT2A and 5-HT2B receptors with potential to treat neuropsychiatric disorders. Designated KB-128, it could be developed to treat disorders that can be modulated though 5-HT2C receptors, including schizophrenia, Alzheimer’s psychosis, depression, obesity and addiction.
Shanghai Zhigen Pharmaceutical Technology Co. Ltd. has identified aminoketone compounds with improved chemical stability that are potentially useful for the treatment of depression, post-traumatic stress, obsessive-compulsive disorder, pain and anxiety disorders.
The study of six types of mental illnesses in a thousand brain regions has demonstrated the differences between individuals within each disorder. Using magnetic resonance images (MRI), scientists from Monash University in Australia analyzed the brain changes and built individual maps for each psychiatric disorder. Their results revealed differences between people with the same diagnosis, which could help refine assessments.
The study of six types of mental illnesses in a thousand brain regions has demonstrated the differences between individuals within each disorder. Using magnetic resonance images (MRI), scientists from Monash University in Australia analyzed the brain changes and built individual maps for each psychiatric disorder. Their results revealed differences between people with the same diagnosis, which could help refine assessments.
